Phase 1/2, Open-label Study of Bosutinib Administered in Combination With Capecitabine in Subjects With Solid Tumor and ErbB2 Negative Locally Advanced or Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Bosutinib (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Glioblastoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 02 Jun 2011 Actual patient no (32) added as reported by ClinicalTrials.gov.
- 02 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.